This is a preview of subscription content, log in via an institution to check access.
References
Fu A, et al. Budget Impact of a Fixed-Dose Combination Therapy of Lesinurad and Allopurinol for Second-Line Gout Therapy: a US Commercial Health Plan Perspective. 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMS14, 19 May 2018. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/80329?pdfid=53858.
Khanna P, et al. Cost-Effectiveness of a Fixed-Dose Combination Therapy of Lesinurad and Allopurinol for Second-Line Gout Therapy: a US Payer Perspective. 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMS33, 19 May 2018. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/79744?pdfid=53867.
Rights and permissions
About this article
Cite this article
Allopurinol/lesinurad cost effective for second-line gout therapy. PharmacoEcon Outcomes News 805, 7 (2018). https://doi.org/10.1007/s40274-018-5009-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5009-9